Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-250
- Development stage
- Preclinical
- Lead developer
- INVO BioScience
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NY-250 is a preclinical-stage targeted alpha therapy (TAT) being developed by NAYA Therapeutics (a subsidiary of NAYA Biosciences) for the treatment of hepatocellular carcinoma (HCC). The therapeutic candidate consists of a targeting moiety directed against the Epithelial Cell Adhesion Molecule (EpCAM) labeled with the alpha-emitting radioisotope Astatine-211 (211At). EpCAM is a transmembrane glycoprotein that is frequently overexpressed in various epithelial tumors, including HCC, and is often associated with cancer stem cells and poor clinical outcomes. By specifically binding to EpCAM-expressing tumor cells, NY-250 delivers high-energy, short-range alpha radiation directly to the cancer site, inducing lethal double-strand DNA breaks while minimizing exposure and damage to surrounding healthy tissues.
- Other names
- Astatine-211 EpCAM-targeted alpha therapyAstatine211 EpCAM-targeted alpha therapyAstatine 211 EpCAM-targeted alpha therapy
02
Targets
EPCAM (Epithelial cell adhesion molecule)
Beyond the preview
Go deeper on NY-250.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-250.